January 17, 2022

Targovax granted Patents for ONCOS-102 in combination with chemotherapy in China and Japan

Oslo, 17 January 2022: Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announce that pa...
Read more
January 13, 2022

BONESUPPORT signs distribution agreement with OrthoPediatrics

Lund, Sweden, 15:30 CET, 22-01-13 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company has entered into a...
Read more
January 13, 2022

Oncopeptides phase 3 OCEAN study published in the Lancet Haematology

STOCKHOLM — January 13, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat h...
Read more
January 12, 2022

Targovax ASA: Targovax awarded NOK 8.2m grant by Innovation Norway

Oslo, Norway, 12 January 2022 – Targovax ASA (OSE: TRVX) a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, to...
Read more
January 11, 2022

Fusion Pharmaceuticals Announces Research Collaboration With 48Hour Discovery To Develop Peptide-Based Radiopharmaceuticals

HAMILTON, Ontario and BOSTON, Jan. 11, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing...
Read more
January 11, 2022

Fusion Pharmaceuticals Announces Research Collaboration With Pepscan To Develop Peptide-Based Radiopharmaceuticals

HAMILTON, ON and BOSTON, Jan. 11, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing...
Read more
January 10, 2022

Fusion Pharmaceuticals Announces Nomination Of First Targeted Alpha Therapy Candidate In Collaboration With AstraZeneca To Advance Into IND-Enabling Studies For Phase 1 Development

Candidate Combines Fusion's Targeted Alpha Therapy (TAT) Technology with an AstraZeneca Bispecific Antibody HAMILTON, Ontario and BOSTON, Jan. 10, 2022 /PRN...
Read more
January 10, 2022

Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology

Collaboration will combine Carisma’s engineered macrophage technology with Moderna’s mRNA and LNP technologies to generate and develop in vivo CAR-M therapeutics Multi...
Read more
January 7, 2022

Nordic Nanovector Provides update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular Lymphoma

slo, Norway, 7 January 2022 Nordic Nanovector ASA (OSE: NANOV) provides an update on the timeline for PARADIGME, its ongoing pivotal Phase 2b trial of Betalutin® (177Lu l...
Read more
January 5, 2022

Hemab Therapeutics Appoints John Maraganore as Chair of Board of Directors and Welcomes New Additions to Board and Leadership Team

Experts in clinical development and finance join to advance first-in-class prophylactic therapies for rare bleeding disorders and thrombosis Hemab Therapeutics Appoints John Ma...
Read more